2/3—Russian vaccine 91·6% efficacy; Oxford 76% 22-90 days after 1 dose
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
We did a randomised, double-blind, placebo-controlled, phase 3 trial at 25 hospitals and polyclinics in Moscow, Russia. Between Sept 7 and Nov 24, 2020, 21 977 adults were randomly assigned to the vaccine group (n=16 501) or the placebo group (n=5476). 19 866 received two doses of vaccine or placebo and were included in the primary outcome analysis. From 21 days after the first dose of vaccine (the day of dose 2), 16 (0·1%) of 14 964 participants in the vaccine group and 62 (1·3%) of 4902 in the placebo group were confirmed to have COVID-19; vaccine efficacy was 91·6% (95% CI 85·6–95·2). Most reported adverse events were grade 1 (7485 [94·0%] of 7966 total events). 45 (0·3%) of 16 427 participants in the vaccine group and 23 (0·4%) of 5435 participants in the placebo group had serious adverse events; none were considered associated with vaccination. Four deaths were reported during the study (three [<0·1%] of 16 427 participants in the vaccine group and one [<0·1%] of 5435 participants in the placebo group), none of which were considered related to the vaccine.
Sputnik V COVID-19 vaccine candidate appears safe and effective
The vaccine uses a heterologous recombinant adenovirus approach. The use of two varying serotypes, which are given 21 days apart, is intended to overcome any pre-existing adenovirus immunity in the population. Among the major COVID vaccines in development to date, only [this vaccine] uses this approach. The recombinant adenovirus route to protection is shared with the Oxford–AstraZeneca vaccine, which uses a chimpanzee adenovirus (ChAdOx), the Johnson & Johnson vaccine that uses only Ad266 whose detailed results are expected soon, and the CanSinoBIO-Beijing Institute of Biotechnology Ad5-based vaccine whose phase 3 trial began in September, 2020. The carrier viruses are modified and cannot initiate a productive infection; they enter cells, express the spike protein, and then stop.
Pfizer Vaccine found 92% effective in Israel, in first controlled result outside trials
[Media report.] Pfizer’s coronavirus vaccine is showing 92 percent effectiveness in Israel, according to the world’s first big controlled investigation on how it works outside of clinical tests. Only 31 out of 163,000 Israelis vaccinated by Maccabi Healthcare Services were diagnosed with COVID-19 in their first 10 days of full-strength protection, its top vaccine statistics analyst, Anat Ekka Zohar, told The Times of Israel on Thursday.
Just 0.04% of Israelis caught COVID-19 after two shots of Pfizer vaccine
[Media report.] A total of 371 out of 715,425 Israelis who passed at least a week after receiving two doses of the Pfizer coronavirus vaccine have contracted the virus – 0.04%, with 16 being sent to the hospital – according to a Health Ministry report released on Thursday.
Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine [Oxford]
[Preprint.] 17,177 baseline seronegative trial participants were eligible for inclusion in the efficacy analysis, 8948 in the UK, 6753 in Brazil and 1476 in South Africa. The primary analysis of overall vaccine efficacy >14 days after the second dose based on the prespecified criteria was 66.7% (57.4%, 74.0%). Vaccine efficacy after a single standard dose of vaccine from day 22 to day 90 post vaccination was 76% (59%, 86%). A single standard dose of the vaccine reduced PCR positivity by 67%. After the second dose, the schedule reduced PCR positivity by 49.5% overall. These data indicate that ChAdOx1 nCoV-19, used in the authorised schedules, may have a substantial impact on transmission by reducing the number of infected individuals in the population.
Missed an update? View past issues.